Form 4: Immuneering Corp Director Robert J. Carpenter Granted 33,350 Stock Options

Immuneering Corp Director Robert J. Carpenter has been granted 33,350 stock options with an exercise price of $1.90, aligning his interests with shareholder value.

Summary

• Robert J. Carpenter, a Director of Immuneering Corp (IMRX), was granted 33,350 stock options.
• The transaction date for this grant was June 13, 2025.
• The exercise price for these stock options is $1.90 per share.
• The options have an expiration date of June 13, 2035.
• The options will vest in equal monthly installments over a one-year period, commencing on July 13, 2025.
• Full vesting and exercisability will occur on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first.
• Following this transaction, Robert J. Carpenter beneficially owns 33,350 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. It is a routine compensation event and not indicative of major operational changes.

Positives

• The grant of stock options to Director Robert J. Carpenter helps align his financial interests directly with the long-term performance and shareholder value of Immuneering Corp.

Future Outlook

The stock options granted to Director Robert J. Carpenter are subject to a one-year vesting schedule, commencing July 13, 2025, and becoming fully vested by June 13, 2026, or the 2026 annual meeting, whichever is earlier. This indicates a future increase in the director's direct equity ownership as the options vest and potentially are exercised.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, serving as a form of long-term incentive compensation designed to align the interests of directors with those of shareholders.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across various industries, including biotechnology, to incentivize long-term performance and align interests with shareholders.
• The vesting schedule over one year is a common approach for such grants, ensuring continued engagement and performance over a defined period.
• While specific comparable companies or projects are not detailed in this filing, this type of equity compensation is widely observed in companies of similar size and stage to Immuneering Corp.

Corporate Governance

Related Party Transactions

• The grant of 33,350 stock options to Robert J. Carpenter, a Director of Immuneering Corp, constitutes a related party transaction as it involves a transaction between the company and an insider. This is a standard form of equity compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value, potentially leading to more focused efforts on long-term company growth.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options will begin vesting in monthly installments starting July 13, 2025.
• The options will become fully vested and exercisable by June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first.

Key Dates

Keywords

Immuneering Corp, IMRX, Stock Option, Director Compensation, Equity Grant, Insider Transaction, SEC Form 4, Corporate Governance